SCHEMBL44432

SCHEMBL44432

Cl[Cr]Cc1ccccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL992532 0.77
SCHEMBL8359473 0.75 CALM1 (0.50)
Diphenylmethane SCHEMBL28630998 0.73 CALM1 (0.75)
SCHEMBL11457819 0.73 ALDH1A1 (0.55)
SCHEMBL2032974 0.69 CALM1 (0.50)
SCHEMBL2684480 0.67 ALDH1A1 (0.48)
SCHEMBL8830370 0.67 CALM1 (0.41)
(Chloromethyl)Benzene SCHEMBL7413 0.65
SCHEMBL21317609 0.65 CALM1 (0.53)
(Chloromethyl)Benzene SCHEMBL1331085 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 783 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-8182643-A None JP disclosed
US-12037585-B2 Oligonucleotides for tissue specific gene expression modulation UNIVERSITY OF MASSACHUSETTS (US) 2024-07-16 US disclosed
US-12024706-B2 Modified oligonucleotides targeting SNPs UNIVERSITY OF MASSACHUSETTS (US) 2024-07-02 US disclosed
US-20240200061-A1 TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES ALNYLAM PHARMACEUTICALS, INC. 2024-06-20 US disclosed
US-12005074-B2 Extrahepatic delivery ALNYLAM PHARMACEUTICALS, INC. (US) 2024-06-11 US disclosed
EP-4376953-A1 PEPTIDE LIGANDS FOR CNS AND OCULAR DELIVERY OF RNAI COMPOUNDS Alnylam Pharmaceuticals, Inc. (US) 2024-06-05 EP disclosed
US-20240175028-A1 DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA ALNYLAM PHARMACEUTICALS, INC (US) 2024-05-30 US disclosed
EP-4367237-A2 BIS-RNAI COMPOUNDS FOR CNS DELIVERY Alnylam Pharmaceuticals, Inc. (US) 2024-05-15 EP disclosed
US-20240141362-A1 MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY UNIV MASSACHUSETTS (US) 2024-05-02 US disclosed
US-20240132892-A1 OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72 UNIV MASSACHUSETTS (US) 2024-04-25 US disclosed
EP-0810875-A1 MULTIFUNCTIONAL ENZYME PHAIRSON MEDICAL INC. (SE) 1997-12-10 EP disclosed
WO-1997045423-A1 PHARMACEUTICAL FOR TREATING OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS TROPHIX NEUROSCIENCE INC. (US) 1997-12-04 WO disclosed
EP-0789564-A1 POLYNUCLEOTIDE COMPOSITIONS SUPRATEK PHARMA, INC. (CA) 1997-08-20 EP disclosed
US-5656611-A MODIFIED POLYNUCLEOTIDE AND COPOLYMER HAVING POLYETHER SEGMENTS AND POLYCATION SEGMENTS; STABILIZING POLYNUCLEIC ACIDS AND INCREASING ABILITY TO CROSS CELL MEMBRANES SUPRATEK PHARMA INC. (CA) 1997-08-12 US disclosed
WO-1996040056-A1 POLYETHER BLOCK COPOLYMER MICELLAR COMPOSITIONS FOR TARGETING BIOLOGICAL AGENTS SUPRATEK PHARMA INC. (CA) 1996-12-19 WO disclosed
WO-1996030052-A1 LIMBIC SYSTEM-ASSOCIATED MEMBRANE PROTEIN AND DNA UMDNJ, NEW JERSEY'S UNIVERSITY OF THE HEALTH SCIENCES (US) 1996-10-03 WO disclosed
WO-1996024371-A1 MULTIFUNCTIONAL ENZYME PHAIRSON MEDICAL, INC. (SE) 1996-08-15 WO disclosed
JP-H08182643-A WET ADSORBING MATERIAL FOR CLEANING PRODUCT AND SURFACE YISSUM RES DEV CO OF HEBREW UNIV OF JERUSALEM 1996-07-16 JP disclosed
WO-1996016541-A1 POLYMER LINKED BIOLOGICAL AGENTS SUPRATEK PHARMA, INC. (CA) 1996-06-06 WO disclosed
WO-1996015778-A1 POLYNUCLEOTIDE COMPOSITIONS SUPRATEK PHARMA, INC. (CA) 1996-05-30 WO disclosed